Apatinib combined with temozolomide in diffuse midline glioma: a novel and effective therapy.

ABSTRACT:

Purpose

Diffuse midline glioma (DMG), H3 K27M-mutant is a type of diffuse high-grade glioma that occurs in the brain midline carrying an extremely poor prognosis under the best efforts of surgery, radiation, and other therapies. For better therapy, we explored the efficacy and toxicity of a novel therapy that combines apatinib and temozolomide in DMG.

Methods

A retrospective analysis of 32 patients with DMG who underwent apatinib plus temozolomide treatment was performed. Apatinib was given 500 mg in adults, 250 mg in pediatric patients once daily. Temozolomide was administered at 200 mg/m²/d according to the standard 5/28 days regimen. The main clinical data included basic information of patients, radiological and pathological characteristics of tumors, treatment

SUBMITTER: Li YA 

PROVIDER: S-EPMC11193221 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature